Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Advances in Translational Models to Study Fibrosis

Available via

WEBINAR

Advances in Translational Models to Study Fibrosis

Tuesday, April 17, 2018, 9:00 AM - 6:00 PM EDT

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

The Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

Fibrosis is a common pathology in many chronic diseases and is often associated with disease progression. Many extracellular matrix macromolecules, as well as their regulators and modifiers have been identified as potential disease targets or biomarkers by extensive studies in numerous preclinical animal models of fibrosis. However, therapeutics development depends on in vitro experimental systems that model pathological processes in order to build assays for screening, mechanistic characterization and target disease link evaluation. In vitro fibrosis experimental systems have been limited, but a better understanding of shared pathways and the distinctions that lead to fibrosis in different organs is now emerging from technical advances such as proteomics, RNAseq, laser capture microdissection and the availability of clinical materials. The advent of engineered substrata with defined biomechanical properties, the use of stem cells and capabilities for genetic modification have also contributed to the design of increasingly sophisticated in vitro models of fibrosis. When coupled with co-culture and organoid technologies, these advances enable modeling of cell and tissue interactions in normal and fibrotic settings. This symposium will review what is known about the cell and molecular biology of fibrosis and reparative healing, discuss current model systems, and consider the challenges and opportunities for future innovation.

Registration

Member
$60
Nonmember Academia, Faculty, etc.
$105
Nonmember Corporate, Other
$160
Nonmember Not for Profit
$105
Nonmember Student, Undergrad, Grad, Fellow
$70
Member Student, Post-Doc, Fellow
$25
Member
$30
Nonmember Academia, Faculty, etc.
$65
Nonmember Corporate, Other
$85
Nonmember Not for Profit
$65
Nonmember Student, Undergrad, Grad, Fellow
$45
Member Student, Post-Doc, Fellow
$15
Deadline:
0
days
left

Organizers

Scott MacDonnell, PhD, Regeneron
Scott MacDonnell, PhD, Regeneron
Ignacio Juncadella, PhD, Boehringer Ingelheim
Ignacio Juncadella, PhD, Boehringer Ingelheim
Julie Hawkins, PhD, Boehringer Ingelheim
Julie Hawkins, PhD, Boehringer Ingelheim
John Hambor, PhD, Boehringer Ingelheim
John Hambor, PhD, Boehringer Ingelheim
Sara Donnelly, PhD, The New York Academy of Sciences
Sara Donnelly, PhD, The New York Academy of Sciences
Sonya Dougal, PhD, The New York Academy of Sciences
Sonya Dougal, PhD, The New York Academy of Sciences

Speakers

Galina Bogatkevich, MD, PhD, Medical University of South Carolina​
Galina Bogatkevich, MD, PhD, Medical University of South Carolina​
Joseph Bonventre, MD, PhD, Harvard Medical School
Joseph Bonventre, MD, PhD, Harvard Medical School
Mary E. Choi, MD, Weill Cornell Medicine
Mary E. Choi, MD, Weill Cornell Medicine
Jonathan Garlick, DDS, PhD, Tufts University
Jonathan Garlick, DDS, PhD, Tufts University
Robert Lafyatis, MD, University of Pittsburgh
Robert Lafyatis, MD, University of Pittsburgh
Scott MacDonnell, PhD, Regeneron
Scott MacDonnell, PhD, Regeneron
Florian Rieder, MD, Cleveland Clinic
Florian Rieder, MD, Cleveland Clinic
Katalin Susztak, MD, PhD, Perelmann School of Medicine University of Pennsylvania
Katalin Susztak, MD, PhD, Perelmann School of Medicine University of Pennsylvania
Eric White, MD, University of Michigan Medical School
Eric White, MD, University of Michigan Medical School

The Biochemical Pharmacology Discussion Group is proudly supported by:

Lead Supporters

Regeneron

Supporter

Academy Friend

American Chemical Society New York Chapter

Scholar Rock

Promotional Partners

NIH Fibrosis Scientific Interest Group

Tuesday

April 17, 2018

8:30 AM

Breakfast and Registration

9:00 AM

Introduction and Welcome Remarks

Speakers

Sonya Dougal, PhD
The New York Academy of Sciences
Ignacio Juncadella, PhD
Boehringer Ingelheim

Session 1: Emerging strategies for Fibrosis

Session Chairperson
Moderator: Ignacio Juncadella
9:15 AM

Function Follows Form: Three Dimensional Human Tissues to study Scleroderma and Fibrosis

Speaker

Jonathan Garlick, PhD
Tufts Unversity
9:45 AM

Mechanisms of Fibrostenosis in Inflammatory Bowel Diseases

Speaker

Florian Rieder, MD
Cleveland Clinic
10:15 AM

Fibroblast Heterogeneity in Skin Fibrosis

Speaker

Robert Lafyatis, MD
University of Pittsburgh
10:45 AM

Networking Coffee Break

Session 2: Molecular Mechanisms of Pulmonary Fibrosis

Session Chairperson
Moderator: Julie Hawkins
11:15 AM

Understanding the Mechanisms Driving Pulmonary Fibrosis in Scleroderma

Speaker

Galina Bogatkevich, MD, PhD
Medical University of South Carolina
11:45 AM

Matrix Mechanobiology in Lung Fibrosis: Cause, Effect, or Both?

Speaker

Eric White, MD
University of Michigan
12:15 PM

Using Single Cell Sequencing to Identify Distinct Cell Populations from Fibrotic Lung Tissue

Speaker

Scott MacDonnell, PhD
Regeneron
12:45 PM

Networking Lunch

Session 3: Data Blitz Talks

Session Chairperson
John Hambor
1:50 PM

Evaluation of the Antifibrotic Potential of Therapeutics Using In Vitro Human Primary Cell-based Phenotypic Models of Pulmonary and Renal Fibrosis

Speaker

Sharlene Velichko, PhD
Eurofins DiscoverX
1:55 PM

Adhesoban, an Innovative Technology with Major Potential Anti-fibrosis Effects, Prevents Surgical Adhesion Formation in Three Translational Models

Speaker

Cleva Villanueva, MD, PhD
Instituto Politecnico Nacional, Escuela Superior de Medicina

Session 4: Novel Models of Fibrotic Kidney Disease

Session Chairperson
Moderator: John Hambor
2:00 PM

Genetics, Genomics, and Epigenetics of Kidney Fibrosis

Speaker

Katalin Susztak, MD, PhD
Perelmann School of Medicine, University of Pennsylvania
2:30 PM

Human Kidney Organoids as Models for Injury and Fibrosis

Speaker

Joseph Bonventre, MD, PhD
Harvard Medical School
3:00 PM

Novel Role of RIPK3-Dependent Necroptosis Pathway in Kidney and Lung Fibrosis

Speaker

Mary E. Choi, MD
Weill Cornell Medicine
3:30 PM

Networking Coffee Break

4:00 PM

Panel Discussion: Towards Comprehensive Translational Models of Fibrosis

Speaker

Moderator: Scott MacDonnell, PhD
Regeneron
4:45 PM

Closing Remarks

Speaker

Julie Hawkins, PhD
Boehringer Ingelheim
5:00 PM

Networking Reception

6:00 PM

Adjourn